Publications & Presentations
Filter Publications by:
All Programs
-
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 12, 2022By: A. Mato, J. Woyach, J. Brown3, P. Ghia, K. Patel -
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 12, 2022By: M. Wang, N. Shah, W. Jurczak, P. Zinzani, T. Eyre, et. al. -
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results From the Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 10, 2022By: W. Wierda, D. Lewis, P. Ghia, N. Shah, C. Coombs, et. al. -
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 10, 2022By: M. Palomba, M. Patel, T. Eyre, W. Jurczak, D. Lewis, et. al. -
Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 10, 2022By: N. Shah, M. Wang, J. Brown, K. Patel, J. Woyach, et. al. -
LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models
Presented at: San Antonio Breast Cancer SymposiumOn: Dec 8, 2022By: Loredana Puca, Michele Dowless, Carmen Perez, Maria Jesus Ortiz-Ruiz, Gregory Donoho, Andrew Capen, Lysiane Huber, Sarah Bogner, Dongling Fei, Jason R. Manro, Chun Ping Yu, Wei Guo Xu, Rui Wang, Shuang Chen, Mark Hicks, Parisa Zolfaghari, Andrew Faber, Raymond Gilmour, Monica Ramstetter, Matt Chang, Maria Jose Lallena, Xuequian Gong, David M. Hyman, Lillian M. Smyth, Barbara J. Brandhuber, Barry S. Taylor, Anke Klippel -
A Phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER
Presented at: American Society of Clinical Oncology Annual Meeting 2022On: Jun 6, 2022By: K. Jhaveri, R. Jeselsohn, E. Lim, E. Hamilton, K. Yonemori, et. al. -
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase
Presented at: AACR Annual Meeting 2022On: Apr 11, 2022By: L. Roeker, A. Mato1, J. Brown, C. Coombs, N. Shah, et. al. -
Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 12, 2021By: A. Mato, J. Pagel, C. Coombs, N. Shah, N. Lamanna, et. al. -
Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 12, 2021By: M. Wang, N. Shah, A. Alencar, J. Gerson, M. Patel, et. al. -
Preclinical characterization of LOXO-435 (LOX-24350), a potent and highly isoform-selective FGFR3 inhibitor
Presented at: 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsOn: Oct 7, 2021By: J. Ballard, T. Kercher, D. Abraham, R. Brecht, N. Brooks, et. al. -
Preclinical characterization of LOXO-783 (LOX-22783), a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor
Presented at: 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsOn: Oct 7, 2021By: A. Klippel, R. Wang, L. Puca, A. Faber, W. Shen, et. al. -
Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Richter Transformation: Results from the Phase 1/2 BRUIN Study
Presented at: European Society of HaematologyOn: Jun 11, 2021By: A. Mato, N. Shah, N. Lamanna, T. Eyre, W. Jurczak, et. al. -
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study
Presented at: ASCO Annual Meeting 2021On: Jun 4, 2021By: K. Jhaveri, E. Lim, E. Hamilton, C. Saura, T. Meniawy, et. al. -
Outcomes for Recurrent Mantle Cell Lymphoma post-BTK Inhibitor Therapy in Japan; an Administrative Database Study
Presented at: The Japanese Society of HematologyOn: May 14, 2021By: S. Rai, Y. Tanizawa, Z. Cai, M. Tajimi, H. Asou, et. al. -
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Presented at: The LancetOn: May 6, 2021By: Anthony R Mato, MD Nirav N Shah, MD Wojciech Jurczak, MD Chan Y Cheah, MBBS John M Pagel, MD Jennifer A Woyach, MD et al. -
Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor
Presented at: AACR Annual MeetingOn: Apr 10, 2021By: B. Brandhuber, K. Ku, M. Lallena, C. Baquero, R. Choy, et. al. -
Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)
Presented at: AACR Annual MeetingOn: Apr 10, 2021By: S. Bhagwat, B. Zhao, W. Shen, C. Mur2, R. Barr, et. al. -
Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor
Presented at: AACR Annual MeetingOn: Apr 10, 2021By: S. Peng, C. Si, Y. Zhang, R. Van Horn, X. Lin, et. al. -
Preclinical characterization of potent and selective next-generation RET inhibitors
Presented at: AACR Annual MeetingOn: Apr 10, 2021By: G. Kolakowski, E. Anderson, J. Ballard, B. Brandhuber, K. Condroski, et. al. -
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor In Previously Treated CLL/SLL: Results From The Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 7, 2020By: A. Mato, J. Pagel, C. Coombs, N. Shah, N. Lamanna, et. al. -
In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice
Presented at: ASH Annual MeetingOn: Dec 5, 2020By: E. Gomez, W. Wu, J. Stephens, M. Rosendahl, B. Brandhuber -
LOXO-305, a Next Generation, Highly Selective, NonCovalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Presented at: ASH Annual MeetingOn: Dec 5, 2020By: M. Wang, N. Shah, A. Alencar, J. Gerson, M. Patel, et. al. -
LOXO-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations
Presented at: ASH Annual MeetingOn: Dec 9, 2019By: E. Gomez, I. Lippincott, M. Rosendahl, S. Rothenberg, S. Andrews, B. Brandhuber -
Results from the First-in-Human, Proof-of-Concept Phase 1 BRUIN Trial in Pretreated B-Cell Malignancies for LOXO-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor
Presented at: ASH Annual MeetingOn: Dec 8, 2019By: A. Mato, I. Flinn, J. Pagel, J. Brown, C. Cheah, et. al. -
LOXO-305, A Next Generation Non-Covalent BTK Inhibitor, for Overcoming Acquired Resistance to Covalent BTK Inhibitors
Presented at: Society of Hematologic Oncology Annual MeetingOn: Sep 12, 2018By: B. Brandhuber, E. Gomez, S. Smith, T. Eary, S. Spencer, et. al.